Investor Relations

Webcast ImageWebcast
Nuvectra at Cantor Fitzgerald Global Healthcare Conference (Live)
10/01/18 at 4:40 p.m. ET
Nuvectra at Cantor Fitzgerald Global Healthcare Conference
Monday, October 1, 2018 4:40 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $20.65 - 0.18 (0.86%)
ExchangeNASDAQ
Volume160,533
Today's Open$20.79
Previous Close$20.83
Data as of 09/19/18 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $20.65 with a 52 week high of $23.79 and a 52 week low of $7.60.

Recent News

September 14, 2018

Nuvectra® Announces Closing of Follow-On Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

PLANO, Texas, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today the closing of its underwritten follow-on public offering of 3,248,750 shares of its common stock at a price to the public of $21.25 per share, which included the exercise in full by the underwriters of their option to purchase 423,750 additional shares of common stock on the same terms and conditions. Gross proceeds to Nuvectra were approximately $69

Read More >

September 11, 2018

Nuvectra® Announces Proposed Follow-On Stock Offering

PLANO, Texas, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, announced today that it is commencing an underwritten follow-on public offering of its common stock. In addition, Nuvectra intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Nuvectra intends to use the net proceeds from this offering to fund the expansion of product development and commercialization activities, as wel

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Tram Bui
investors@nuvectramed.com

Events
DateTitle
10/01/18 4:40 p.m. ET
Nuvectra at Cantor Fitzgerald Global Healthcare Conference
Location InterContinental New York Barclay Hotel, New York